SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
LOS ANGELES, May 25, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the U.S. Food and Drug Administration’s potential approval of the NDA. Upon release of this information, the Company’s stock price declined materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
